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Abstract Streptococcus pneumonia-associated hemolytic
uremic syndrome (HUS) (pneumococcal HUS) is an uncom-
mon condition mainly observed in young children. Early
recognition is critical, because of the potential to improve
morbidity and mortality. In our review we summarize the
pathophysiology, clinical features, diagnostic difficulties and
management of this potentially under-diagnosed condition.
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Introduction
Hemolytic uremic syndrome (HUS) in children is usually
caused by Shiga-like toxin-producing E. coli (STEC).
However, HUS is also a complication of invasive pneumo-
coccal infection. The purpose of this review is to describe, in
detail, the clinico-pathological entity known as Streptococcus
pneumoniae-associated HUS (pneumococcal HUS). It is
important to discuss this condition separately from other
causes of HUS, because, in our experience, cases continue to
go unrecognized. We address the pitfalls that arise when
trying to make the diagnosis. We highlight the importance of
practicing a conservative approach to the use of blood and
plasma products in these often critically ill patients. We also
show that the acute mortality rate is highest in patients with
S. pneumoniae meningitis complicated by HUS.
Historical perspective
Acute renal injury in the form of nephritis has been
reported in association with pneumococcal disease since
1872 [1, 2]. Councilman, in 1897 [3], noted that nephritis
occurred in 11 out of 102 cases of pneumonia; all the
patients were very young children. Schenk et al., in 1970
[4], described three cases of pneumococcal septicemia
associated with thrombocytopenia and glomerular and
arteriolar thrombosis without mentioning hemolytic anemia
or HUS. In 1971 Fischer et al. [5] described the association
of S. pneumoniae infection with HUS, and, in 1977, Klein
et al. [6] first reported this condition in the English
literature. Early reports indicated that this rare condition
was associated with a very poor clinical outcome. Of the 12
patients reported in the English language literature between
1977 and 1987, 50% died and 67% of the survivors
developed chronic kidney disease or hypertension [6–13].
Incidence and prevalence
Pneumococcal HUS is an uncommon condition and
involves 5% of all cases of HUS in children but 38–43%
of HUS cases not caused by STEC [14, 15]. The incidence
of HUS following invasive pneumococcal infections is
estimated at 0.4–0.6% [16, 17]. Many investigators have
noted that the incidence of pneumococcal HUS may be
substantially higher and is currently underestimated due to
a lack of awareness [14, 17–19]. The prevalence of
pneumococcal HUS is highest among children under 2
years of age and mirrors the overall incidence of invasive
pneumococcal infection. In contrast, this association is
extremely uncommon in adults [20, 21]. Of the 85 cases of
pneumococcal HUS reported in the English literature [6–
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14, 16, 18, 19, 22–38], 72% were associated with
pneumonia and/or empyema, 29% with meningitis, and
5% with pneumonia and meningitis. Spontaneous bacter-
emia, pericarditis, peritonitis, and mastoiditis were noted
infrequently.
Pathophysiology
The precise pathophysiology of pneumococcal HUS has not
been determined. However, there is evidence of a role for
the Thomsen–Friedenreich (TF) cryptantigen [39]. This
antigen is a component of the surface structure of
erythrocytes, platelets and glomerular endothelial cells and
is normally hidden by neuraminic acid. Neuraminidase,
produced by pneumococci, cleaves the n-acetyl neuraminic
acid from the cell surface and exposes the TF antigen. Pre-
formed host IgM antibodies then bind the TF antigen and
are postulated to initiate the cascade of events leading to
HUS. The activated TF antigen is also present on hepato-
cytes, and this may explain the occurrence of transient
hepatic dysfunction in some patients [26, 32].
All serotypes of S. pneumoniae can have neuraminidase
activity capable of unmasking the TF antigen [22].
Therefore, any invasive pneumococcal infection may result
in a range of abnormalities, ranging from isolated hemolytic
anemia to full-blown HUS. Serotypes 14, 6B, 9V, 19, 3, 8,
23F [32] and 19A (unpublished observation) are all
associated with HUS. Theoretically, different serotypes
may produce varying amounts and activities of neuramin-
idase, thereby influencing the likelihood of a patient’s
developing HUS. Some authors have suggested that a
heavy bacterial load increases the individual’s risk of
developing pneumococcal HUS [31]. Evidence for this
hypothesis is based on the relatively high frequency of
patients with empyema-associated pneumonia and the rarity
of patients who present with spontaneous bacteremia or
minor pneumococcal infections. Parenthetically, several
other neuraminidase-producing organisms, including Capno-
cytophaga canimorsus [40, 41] and, possibly, influenza A
virus, are also reported as causes of HUS [42].
Clinical features
Features of pneumococcal HUS usually develop 3 to 13 days
(most at 7 to 9 days) after the onset of pneumococcus-related
symptoms [19, 38]. This chronology is similar to that
described for Shiga-like toxin-producing E. coli-associated
HUS (STEC HUS), in which diarrheal illness typically
occurs 7 days (range 1–14 days) prior to the onset of HUS
[43]. There is no gender predisposition [19]. Children with
pneumococcal HUS are younger at presentation and have
more severe initial hospital courses than those with STEC
HUS [31]. They also have longer periods of oligo-anuria,
more frequent need for acute dialysis (75% vs 59%), longer
hospital stays (33 days vs 16 days), more red blood cell and
platelet transfusions, and a longer duration of thrombocy-
topenia [31]. In our review of the 73 patients reported from
1987 to 2007 [14, 16, 18, 19, 22–38] 10.1% developed end-
stage renal failure (ESRF) and 12.3% died in the acute
phase. These rates are two-to-three-times higher than those
of STEC HUS [43, 44, 45]. However, the acute mortality
rate of pneumococcal HUS not associated with meningitis
is comparable to that of STEC HUS. In contrast, the higher
rates of ESRF and chronic kidney disease do not appear to
be related to the site of S. pneumoniae infection.
The Canadian Paediatric Surveillance Program divided
patients with invasive pneumococcal infection and features
of HUS into two categories [46]. Definite cases were defined
by the presence of thrombotic microangiopathy on renal
biopsy or autopsy. Some authors have modified this strict
definition and consider a positive result of the Coombs’ test
(see later) as evidence of a definitive case in the absence of a
tissue diagnosis [34]. Possible cases were defined as
pneumococcal HUS that could not be differentiated from
pneumococcal sepsis or disseminated intravascular coagula-
tion (DIC) with secondary organ failure. Other authors [32]
have recommended upgrading all possible cases to probable
status, so that the diagnosis is not overlooked.
Whenever there is evidence of renal injury in the context
of pneumococcal infection it is important to maintain a
broad diagnostic perspective. Acute tubular necrosis occurs
in patients with septic shock and DIC. Immune-complex-
mediated acute glomerulonephritis is a rare complication of
pneumococcal infection [1]. In our experience the major
reasons why the diagnosis of pneumococcal HUS may be
overlooked are a lack of familiarity with this rare condition,
a misdiagnosis of DIC, the coexistence of HUS and DIC,
and cases of pneumococcus-associated microangiopathic
hemolytic anemia with only mild renal involvement.
Another possible explanation is the unavailability of a
highly specific laboratory test.
HUS and DIC may be difficult to differentiate from each
other because both may involve microangiopathic hemo-
lytic anemia, thrombocytopenia, and renal injury or failure.
In most cases of HUS, however, fibrinogen levels, and
prothrombin and partial thromboplastin times are normal or
slightly elevated, and there is no active bleeding. Unfortu-
nately, when these two conditions occur in the same patient,
a diagnosis of HUS may be difficult to make with certainty.
Evidence of a thrombotic microangiopathy on renal biopsy
can be helpful, but the clinical instability of many patients
precludes this procedure. Several investigators have pro-
posed that patients who satisfy the criteria for both HUS
and DIC in the setting of pneumococcal infection should be
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considered as probably having HUS and should be treated
accordingly [29, 32].
Early reports suggested that only bacterial isolates from
patients with pneumococcal HUS had detectable neuramin-
idase activity, while pneumococcal isolates of the same
serotype cultured from non-HUS patients had no neur-
amindase activity [11]. These studies erroneously conclud-
ed that detection of neuraminidase activity was a highly
specific diagnostic tool for pneumococcal HUS. Thomsen–
Friedenreich (TF) antigen exposure, an indirect measure of
neuraminidase activity, can be assessed by the peanut
(Arachis hypogaea) lectin-agglutination method. The
fluorescin-labeled peanut agglutinin has a high affinity for
the normally unexposed TF antigen. Peanut lectin activity
was detected in 36 patients with invasive pneumococcal
disease [47]. In this study positive test results were obtained
in 100% (13/13) of patients with pneumococcal HUS, in
67% (6/9) of patients with pneumococcus-associated
hemolytic anemia, and in 43% (6/14) of patients with
uncomplicated invasive pneumococcal disease. These
results suggest that, in the setting of invasive pneumococcal
infection, detectable neuraminidase activity is highly
sensitive (100%), but not specific (48%), for pneumococcal
HUS. This implies that neuraminidase activity is required
but not sufficient to initiate HUS and that other, as yet
unknown, host or environmental factors must be present.
The exposed TF antigen results in a variety of antigen–
antibody interactions, many of which occur on the plasma
membrane of red blood cells. The direct Coombs’ test
detects antibodies that coat these surfaces and gives
positive results in approximately 90% of cases of pneumo-
coccal HUS [39, 48]. In the presence of invasive pneumo-
coccal infection, difficulties in ABO cross-matching or a
positive minor cross-match are useful tools in making the
diagnosis. Unfortunately, there are no data regarding the
incidence of Coombs’ test positivity in non-HUS forms of
pneumococcal infection. While a positive Coombs’ test
result is highly sensitive for pneumococcal HUS, the degree
of specificity is still unclear.
Renal pathology
The histological findings in pneumococcal HUS are similar
to those in STEC HUS. Fibrin thrombi are seen in the
glomerular capillaries in both forms of HUS. Renal cortical
necrosis may be present [6]. Occasionally, the fibrin
thrombi can extend beyond the capillaries into the afferent
arterioles [6]. Varying degrees of mesangial proliferation,
focal or widespread glomerulonephritis, crescent formation,
and tubular atrophy may occur [6, 11, 12]. The arterial
vessels usually appear normal [12]. Immunofluorescence
staining is negative except for weak staining for IgM [6, 11,
12]. Special staining with immunofluorescence-labeled
peanut agglutinin has been found to be positive in the
glomeruli [6, 11, 13, 22] and tubules [12] of several
patients. This test is not widely available. These findings
support the role of the TF antigen–IgM antibody interaction
in the pathogenesis of pneumococcal HUS [12].
Management
The management of pneumococcal HUS is supportive.
Controlling the abnormalities caused by the renal failure,
anemia, and thrombocytopenia is essential. In addition,
dialysis or hemodiafiltration is often required to maintain
electrolyte and fluid balances and adequate nutrition in
oligo-anuric patients. Because of the significant incidence
of antibiotic resistance in the community, the American
Academy of Pediatrics recommends empirically treating
critically ill children with possible or proven invasive
pneumococcal infections with both vancomycin and an
extended-spectrum cephalosporin [35, 49]. Theoretically,
because anti-TF IgM antibodies are integral to the patho-
genesis, additional pre-formed antibody administration via
fresh frozen plasma or unwashed blood products should be
avoided. Fresh frozen plasma should be avoided unless
there is active bleeding. Furthermore, it is preferable to
transfuse washed red blood cells or platelets. More than
95% of the plasma can be effectively removed from blood
products by dextran-washing [19]. When hemodiafiltration
is performed in young children it is important to avoid
priming the dialysis system with unwashed blood products.
There is no evidence that plasmapheresis is of value.
Several authors have attributed the recent decrease in
mortality rate to earlier recognition and a more conservative
approach to transfusion with washed blood products [25,
33]. It remains to be seen whether the routine administra-
tion of the seven-valent pneumococcal vaccine to infants
has effectively decreased the incidence of pneumococcal
HUS.
Outcomes
Since 1987, 73 children [14, 16, 18, 19, 22–38] with
pneumococcal HUS have been reported in the English
language literature. Of these, 12.3% (9/73) died; 10.1%
(7/69) progressed to ESRF; and 16% (11/69) survived, with
chronic kidney disease or hypertension. Detailed clinical
[33] and follow-up data [34] were unavailable for four
patients. The improved mortality rate in the past 20 years
may have been the result of the advances in critical care
medicine as opposed to changes in disease virulence [31].
A careful analysis of the 69 children with comprehensive
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clinical data [14, 16, 18, 19, 22–32, 34–38] reveals that
only 28% of the patients presented with meningitis.
However, 88% of the deaths occurred in this subgroup
(clinical data available on 8/9 patient deaths). The estimated
mortality rate of pneumococcal meningitis in children
without HUS is 8–10% [50], while the mortality rate in
patients with pneumococcal meningitis complicated by
HUS is 37% (7/19) [16, 22, 23, 26, 29–31, 34]. In marked
contrast, pneumococcal HUS not associated with meningi-
tis has a mortality rate of only 2% [14, 16, 18, 19, 22, 24–
32, 34–38].
The two largest case series published to date support the
notion that the acute mortality rate is largely dependant on
the site of infection. In 2002 Brandt et al. [31] described 12
patients: nine had isolated pneumonia and three had
pneumococcal HUS with meningitis. There were no deaths
in either group. Two of the seven patients with long-term
follow-up developed ESRF, and five had normal renal
function. In 2001, Nathanson and Deschenes [29] reported
their observations on 11 patients: eight had meningitis and
three had pneumococcal HUS with an isolated pneumonia.
There were no deaths in patients with pneumonia; two
developed mild chronic kidney disease, and one recovered
completely. Four of the eight patients with meningitis died,
three progressed to ESRF, and one recovered completely.
The poor prognosis seen in patients with pneumococcal
meningitis complicated by HUS is consistent with the
earlier observation that the severity of pneumococcal
meningitis is related to neuraminidase activity and TF
exposure in the central nervous system [51].
Conclusion
Pneumococcal HUS is a well-characterized condition that
may still be under-recognized. The absence of a consistent
case definition and the lack of a specific laboratory test may
play a role in under-diagnosis and late detection. The potential
to improve morbidity and mortality, by the avoidance of
plasma infusion or exchange and transfusion of unwashed
blood products, makes early recognition important. From a
practical point of view, pneumococcal HUS should be
suspected when one or more of the following occurs in the
context of HUS: a toxic patient, pneumonia, meningitis or
other evidence of invasive infection, a hemolytic anemia
without reticulocyte response, a positive Coombs’ test result
or a positive minor cross-match.
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Questions (Answers appear following the reference list)
1. Which of the following molecules is involved in the
pathogenesis of pneumococcal HUS?
A. Globotriaosylceramide (Gb3)
B. von Willebrand factor cleaving protease ADAMTS13
C. Neuraminic acid
D. Factor H
E. Membrane co-factor protein (CD46)
2. Which of the following laboratory findings is NOT
associated with pneumococcal HUS?
A. Microangiopathic hemolytic anemia
B. Positive result of a Coombs’ test
C. Positive result of a peanut lectin activity test
D. Hypocomplementemia
E. Normal or slightly elevated prothrombin time
3. Which of the following is associated with a poor
outcome in pneumococcal HUS?
A. Patient age
B. Serotype of S. pneumoniae
C. Meningitis
D. Severity of anemia
E. All of the above
4. In the treatment of a patient with pneumococcal HUS
all of the following should be avoided EXCEPT?
A. Continuous venovenous hemofiltration (CVVH)
B. Transfusion of unwashed packed red blood cells
(PRBCs)
C. Plasmapheresis
D. Fresh frozen plasma
E. Transfusion of unwashed platelets
5. In the comparison of children with pneumococcal
HUS and STEC HUS, which of the following is
FALSE?
A. Children with pneumococcal HUS are more likely
to require acute dialysis
B. There is no gender predisposition in either form of
HUS
C. Children with pneumococcal HUS are likely to be
older at presentation
D. Children with pneumococcal HUS are more likely
to develop chronic kidney disease
E. Children with pneumococcal HUS are more likely
to require red blood cell and platelet transfusions
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